Assessing the Global Burden of IgA Nephropathy (IgAN) in Patients Receiving Hemodialysis: A Real-World Study Using DOPPS Data

NCT07607002 | Completed

• 1 other identifier: OAK-ISS-2025-002154
• Study Type: observational
• Target: 70,000
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study leverages the global Dialysis Outcomes and Practice Patterns Study (DOPPS) database to generate real-world evidence on the burden of IgAN in patients who progress to kidney failure and require maintenance hemodialysis (HD). We will first aim to understand prevalence of IgAN in a global cohort of in-center HD patients. The second and third objectives aim to quantify the patient burden of IgAN using a two-step approach: first, a detailed single-arm evaluation of outcomes within the IgAN population; second, a matched comparison to the broader HD population.

Conditions

IgAN - IgA Nephropathy

Keywords

IgAN; Dialysis

Outcome Measures

Primary Outcomes (1)

• IgAN

  1996-2023

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

This is a retrospective observational study using data from Phases 1 through 7 (1996-2023) of the DOPPS, a multinational, prospective cohort study of in-center HD patients across more than 20 countries. DOPPS collects standardized data on demographics, comorbidities, laboratory values, treatments, hospitalizations, and mortality, as well as many validated PROs. To ensure national representativeness and reduce selection bias, DOPPS uses a stratified random sampling approach to select dialysis facilities and patients within each participating country. Regional representation includes Europe, Japan, North America, China, Oceania, and the Gulf Cooperation Council (GCC).

You may qualify if:

• Age ≥ 18 years at the time of enrollment
• Receiving in-center HD treatment at a participating dialysis facility
• Able to provide informed consent, if required by local regulations or ethics boards

Sponsors & Collaborators

• Arbor Research Collaborative for Health: lead

MeSH Terms

Conditions

Glomerulonephritis, IGA

Condition Hierarchy (Ancestors)

Glomerulonephritis; Nephritis; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Autoimmune Diseases; Immune System Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Distinguished Research Scientist

Study Record Dates

• First Submitted: May 19, 2026
• First Posted: May 26, 2026
• Study Start: January 1, 1996
• Primary Completion: December 31, 2023
• Study Completion: December 31, 2023
• Last Updated: May 26, 2026

Record last verified: 2026-05